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Summary 
A cDNA library was prepared from peripheral blood lymphocytes of an autoimmune patient 
with primary Sj6grens' syndrome. The cDNA library  was  screened with the patients own 
autoimmune serum being monospecitic for the nuclear autoantigen La/SS-B. Thereby an alternative 
type of La mRNA was identified that differed from the known La mRNA due to an exchange 
of the exon 1. Sequencing of the genomic region between the exons 1 and 2 showed that the 
alternative  5'-end is a part of the intron. In addition, the presence of an alternative  promoter 
site, which exists within the intron downstream of the exon 1, became evident. In consequence, 
the alternative  La mRNA is the result of a promoter switching combined with an alternative 
splicing mechanism. In the intron, further transcription factor binding sites, including a NF-xB 
element, were identified leading to the suggestion that the expression of the gene encoding for 
the nuclear autoantigen La/SS-B alters in dependence on disease conditions. 
T 
he basic mechanisms for development of autoimmunity, 
including the development of autoantibodies directed to 
nuclear antigens (ANAs) I, in patients with systemic lupus 
erythematosus (SLE) or primary Sj6grens' syndrome (pSS) 
are not understood. It is assumed that unknown genomic 
prerequisites  together with viruses may play a role during 
development of autoimmunity. Especially herpesviruses, in- 
cluding the Epstein Barr virus as well as exogenous or en- 
dogenous retroviruses,  were discussed as possible causative 
agents of these diseases (1, 2). An involvement of retroviruses 
in pSS is supported by (a) an appearance  of antibodies to 
retroviral proteins in patients with pSS and (b) the isolation 
of an A-type retroviral  particle in lymphoblastoid cells ex- 
posed to homogenates of salivary tissue from patients with 
pSS (3).  In  addition,  the human immunodeficiency virus 
(HIV), can produce a clinical syndrome and immunologic 
changes similar to those seen in pSS, including the develop- 
ment of ANAs (4). Nonetheless, even if these or other viruses 
are involved in autoimmunity in pSS and SLE patients, the 
mechanism by which viruses  can lead to the development 
1 Abbreviations used in this paper: ANA, autoantibodies directed to nuclear 
antigen; pSS, primary Sj6grens' syndrome; SLE, systemic  lupus erythem- 
atosus. 
of ANAs remains obscure, as these autoantibodies are at least 
partially the product of an autoantigen driven oligoclonal B 
cell response  (5, 6). 
One of the targets of an ANA system is the nuclear au- 
toantigen La/SS-B (7). La protein has been suggested to be 
involved in transcription termination of RNA polymerase 
III and internal initiation of translation of at least poliovirus 
mRNA (8-10).  Up to now more than 20 La cDNAs have 
been isolated by six independent groups and no dramatic differ- 
ences had been observed (11-16). The transcription of this 
described type of La mKNA was suggested to occur from 
a GC-rich promotor region upstream of the exon 1 lacking 
a TATA-element, leading to the conclusion that La protein 
belongs to the housekeeping proteins (17). 
In case of some protooncogenes, inflammatory mediators, 
signal transduction components, proteins involved in the im- 
mune response, transcription factors, growth factor receptors, 
and some other housekeeping proteins, in addition to the 
respective translatable mRNA, an alternative mRNA has been 
described.  Usually the exon 1 is replaced in the respective 
alternative mKNA. The alternative 5'-terminus alters the prop- 
erties  of the mRNAs dramatically  as it contains GC-rich 
regions and/or additional less functional AUGs upstream of 
the major open reading frame (18). Due to their unusual 5'- 
terminal structure, such mKNAs were hypothesized to ei- 
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represent intermediates that can be further processed depending 
on the tissue  (18). 
Here we describe the isolation and characterization of such 
an alternative type of mRNA derived from the gene encoding 
for the autoantigen  La/SS-B. 
Materials  and Methods 
Preparation of a cDNA  Library from  the PBL of a Patient with 
loSS.  RNA was isolated  from PBL of a patient with pSS (Ma) 
as basically described by Chirgwin et al. (19) using modifications 
according to Semsei and Cutler (20).  Poly(A) § mRNA was iso- 
lated from the RNA preparation using oligo(dT)-column chroma- 
tography (20). The cDNAs were synthesized using the ZAP-cDNA 
synthesis kit and ligated to the Uni-ZAPXR vector arms (Stratagene, 
Heidelberg, Germany, 21). The k-library was packaged by Giga- 
pack II Gold packaging extract (Stratagene), plated and amplified 
in the Escherichia coli cell lines PKL-F' and XL1-Bhe, respectively. 
The complexity of the library was  106 pill. 
Immunoscreening.  Immunoscreening was performed using the 
patient's anti-La serum (10 ml). Before use, the serum was exten- 
sively preadsorbed to a Sepharose 4B column (5 ml), which had 
been covalently linked to a total extract obtained from E. coli (strain 
Y1090) at a concentration of 10 mg/ml gel. The first screening 
was followed by second and third screenings  using the antibody 
solution left from the first screening step. The clones were checked 
in parallel  with  a cell culture supernatant  of a hybridoma line 
producing a monoclonal anti-La antibody (termed La4B6, obtained 
by immunization of BALB/c mice with a recombinant human La 
protein; Tr6ster, H., T. Metzger, K. Klein, G. Pollak,  I. Semsei, 
M. Schwemmle,  G. Pruijn, W. van Venrooij,  and M. Bachmann, 
unpublished results).  The immunoscreening was performed fol- 
lowing the protocol of Mierendorf et al. (22). A total amount of 
4  x  10  s recombinant phages were screened  and five positive  La 
cDNAs were isolated with the patient's antiserum. In addition 12 
cDNAs encoding for IgG heavy chains were coisolated, which was 
not surprising as the cDNA library was constructed from PBL and 
screened with anti-human IgG antibodies. The coisohted IgG heavy 
chain cDNAs were differentiated from the La cDNAs by (a) their 
different restriction enzyme analysis pattern and (b) sequencing. 
Isolation and storage of the clones was done according to Sam- 
brook et al. (23). Phagemids (pBluescript SK(-)) were excised from 
k  phages  during  an  in  vivo  excision  procedure  described by 
Stratagene using the filamentous helper phage strain R408 and the 
bacterial strain XL1-Blue as a host (23). 
Construction of Deletion Clones.  The two clones termed La19 and 
La23,  which contained the largest inserts,  were selected for se- 
quencing. The other cDNAs were only sequenced  from the Y- 
and the 5'-end to characterize them as La cDNAs. DNA was pre- 
pared from small scale cultures (up to 12 ml) using the protocol 
of Holmes and Quigley (24) modified according to Sambrook et 
al. (23). To create deletion clones the method originally described 
by Henikoff (25) was used. The DNA to be deleted was cut with 
BstXI and EcoKI from which site deletions started. 
Construction of a  Genomic Subclone.  For  subcloning  of the 
genomic fragment derived from the charon phage kLa2-1  (17), 
which  was  kindly  provided by  Dr.  Keene  (Duke  University, 
Durham, NC), the "shot gun" cloning technique was used. 13 ng 
of M.a2-1 DNA was digested with EcoRI (5 U//zg DNA in 2x 
One-Phor-All-Buffer  PLUS [Pharmacia LKB, Freiburg, Germany]). 
In earlier studies Chambers et al. (17) had shown that a digestion 
of genomic DNA with EcoRI resulted among other fragments 
in a 4.6-kb fragment of the La gene. According to our calculations 
the molecular mass of this fragment might be about 4.8 kb. The 
reaction was stopped by the addition of EDTA to a final concentra- 
tion of 17 mM followed by a heat treatment for 20 min at 68~ 
The pBhescript SK(-) vector DNA (Stratagene) was digested with 
EcoRI (2.5 U//~g of DNA) at a concentration of 0.88/~g DNA//~I 
in 2x  One-Phor-All-Buffer PLUS. After dilution (1:4) and an in- 
activation step by heating to 68~  for 20 min, calf intestine phos- 
phatase (CIP; Boehringer Mannheim, Mannheim, Germany) was 
added (0.3 U  CIP//~g DNA) and incubated for 30 min at 37~ 
in the recommended buffer (10x : 0.5 M Tris/HC1, pH 8.5; I mM 
EDTA). The enzyme was inactivated by the addition of EDTA (16 
mM final concentration) in combination with heating for 30 min 
to 75~  The tigation of the EcoRI-fragments with the phosphatase- 
treated EcoKI-digested vector DNA took place in a 10/~1 volume 
at 16~  overnight. The reaction mixture consisted of 200 ng vector 
DNA, 30 ng of EcoRI-fragments in Tris/HC1, pH 7.5 containing 
1 mM ATP, 1 mM dithiothreitol, and 5 mM MgC12. Then the 
ligation reaction was adjusted  to a volume of 100 #1 with H20 
and added to 200/~1 of competent E. coil XL1-Blue cells for trans- 
formation according to Sambrook et al.  (23). The bacteria were 
plated on ampiciUin (150/~g/ml) agar containing 2.5 mM isopropyl 
3-D-thiogalactoside (WIG) and 0.4% (wt/vol) X-Gal in order to 
discriminate religated vector DNA (blue colonies)  from colonies 
containing vectors with inserts (white colonies).  Plasmid  DNAs 
derived from white colonies were found to contain the desired 4.8- 
kb fragment of the La gene. 
Southern Blotting.  DNA was isolated  as basically described by 
Chirgwin et al. (19) using minor modifications according to Semsei 
and Cutler (20). The DNA was digested with EcoRI and 13/~g 
of DNA per lane were loaded on an 0.7% agarose  gel.  The gel 
was run for 16 h with 1.8 V/cm. Southern blotting was performed 
according to Sambrook et al. (23). After transfer onto a positively 
charged Nylon membrane (Boehringer Mannheim) the DNA was 
cross-linked  by UV irradiation with 120 mJ using a Stratalinker 
1800 (Stratagene) followed by a heat treatment for 60 min at 80~ 
Hybridizations  and hbelings of the DNA were performed according 
to the nonradioactive detection system (Boehringer Mannheim). 
The signals were developed using anti-DIG antibodies covalently 
linked to either alkaline phosphatase and CSPD (TRopix, Serva 
Heidelberg, Germany) as substrate (see Fig.  2 A) or peroxidase 
(Boehringer Mannheim)  and  the  enhanced  chemiluminescence 
(ECL) detection system (Amersham-Buchler, Braunschweig,  Ger- 
many) (see Fig.  2, B and C). Between the three hybridizations, 
membrane stripping was performed as follows. The filter was washed 
twice in 0.1% SDS at room temperature followed by a proteinase 
K treatment (1 mg/ml) in 0.1% SDS for 35 min at 55~  and 10 
min at 65~  Afterward the membrane was further stripped as de- 
scribed by Sambrook et al. (23). For this purpose the blot was washed 
with 50% formamide, 2 x  SSPE at room temperature and in the 
same buffer at 65~  for 45 min. The membrane was rinsed in 0.1% 
SDS,  0.1x  SSC  at  room  temperature,  dried  on  3MM-paper 
(Whatman International Ltd., Maidstone, UK) and stored at room 
temperature in the dark and dry. 
PCR.  PCR was performed using a TC9600 Cycler (Perkin- 
Elmer, Uberlingen, Germany). The 50-/~1 assay in lx  Taq buffer 
contained 2 U Taq polymerase (Boehringer Mannheim), 1.5 mM 
MgC12, 5% (vol/vol) DMSO, 200 mM of each dNTP, 20 pmol 
of each primer, and 100 ng of genomic DNA or 1 ng of plasmid 
DNA. Cycling was started by heating for 2 rain to 94~  40 cycles 
followed, each consisting of 15 s at 94~  15 s at 55-60~  de- 
pending on the primer pairs used, and 15-60 s at 72~  depending 
on the length of the resulting fragments. Then the temperature 
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the respective assay were taken, and 1.5/~1 of sample buffer (40% 
sucrose, 0.25% bromophenol blue in H20) was added and applied 
to a 1.5-1.8% agarose (Biozym, Hameln, Germany) gel in TAE 
buffer (40 mM Tris-acetate, pH 8.0; 1 mM EDTA). For determina- 
tion of the molecular weights of the PCR products 250 ng of the 
DNA molecular weight marker VI (Boehringer Mannheim) was 
run in parallel. The gds were run for 10 min at 5 V/cm and 120 
min at 3 V/cm and stained with ethidium bromide. Photographs 
were taken with polaroid film 667. 
DNA  Sequence Analysis.  The DNA  for  sequencing of the 
cDNAs was prepared by alkaline lysis  miniprep method according 
to Sambrook et al. (23). The DNA samples were sequenced using 
the automatic fluorescent DNA sequencing system of the EMBL. 
The sequences were evaluated running the evaluation program 
COMGRA on a 486 PC system.  DNA comparison  and alignments 
were performed using the program package HUSAR of the DKFZ 
(Heidelberg, Germany). 
The genomic sequences were prepared from genomic DNA iso- 
lated from different tissues including PBL of the patient (Ma; [8]) 
with pSS, an SLE patient (p62), and her baby born with AV block 
(p61), as well as several healthy donors, and the subclone derived 
from the genomic clone M.a2-1 (see above), the liver of a tumor 
patient (We), and the embryonic spleen. The genomic sequence 
between the promotor upstream of the exon 1 and the end of the 
exon 2 was determined for the subclone  prepared from the genomic 
clone M.a2-1 (see above) as well as for the genomic DNA of the 
patient (Ma). For that purpose overlapping PCR fragments were 
prepared and sequenced  using the Cycle  Sequencing  Kit from Phar- 
macia LKB and/or the PCR fragments were directly sequenced 
(see below). In the case of the GC-rich region between the exon 
I and the oligo(dT)-tail the PCR fragments prepared were not only 
directly sequenced  but subcloned  into pBluescript and at least three 
subclones were sequenced. 
The following primers were used for sequencing of the genomic 
region between promoter 1 and the exon 2: Pl (GCACTTCACAT- 
GAATGGAGG); P2  (GAGTCGT'IGCTGTTGCTGTTTG);  P3 
(GCACAGGCTCACAAACAGCAAC);  P4 (GCTGTTTGTGAG- 
CCTGTGCGC~GGC);  P5 (GTTCCTTAGATACTCTATGC);  P6 
(CGCTTTACTAGTGCGCGACTGCGCGTTTCC);  P7  (AAG- 
ACGCAATGGGGATGAGG);  P8 (ACCGCCTTCTAGTCTCAC- 
CGAA); P9 (ACAAGCCTTCGGTGAGACTAGA);  P10 (CCC- 
ACCTCCCCAGAAACTTTACAG); Pll (GCACGGGGTAAA- 
CGCCGGAGGGTTC); P12 (CTGAAACCTGATGTGAGCGAT- 
G); P13 (GCCAAATAGGTTTTGCAGGGTG);  P14 (ATGCTTC- 
CAGGAAGTGTACC);  P15 (GTTAGTATGACCACATTCTCCC); 
P16 (GGACCCTTTTGTAGCTTCTC);  P17 (AGTTCAAGACCA- 
GCCTGACC); P18 (CTTCACTTAGCIGG~__.AAGC);  1>19 (CTC- 
AACAAAGCAACACTTTGG); P20 (TCACCATTTTCAGCC- 
ATTGCGG); P21 (GATGACAGATTTTGGCCTCCAG). 
Cycle sequencing was performed using the Cycle Sequencing 
Kit from Pharmacia LKB and the Cycler TC9600 (Perkin-Elmer). 
Four caps were prepared by adding to each 2/~1 of one of the four 
termination mixtures (A, C, G, T) and stored at 4~  until use. 
Then master mixes were prepared consisting of 2 #1 primer solu- 
tions containing up to 10 pmol primer, 5/A of 5 x  sequencing 
buffer, 1 #1 dNTP mix, 1/xl Tth (Thermus thermophilus) DNA 
polymerase (1 U//zl),  1/A c~-[33p]dATP (3,000 Ci/mmol; NEN, 
Dreieich, Germany), and 2/~g of template DNA. 5 #1 of the respec- 
tive master mix were added to each of the four termination mix- 
tures (A, C, G, T). Cycling was started by heating for 2 min to 
95~  Then 25 (to 50) cycles followed, each consisting of 30 s at 
95~  36 s at 55~  and 84 s at 72~  Finally the reaction mix- 
tures were held for 5 rain at 72~  and cooled to 4~  until the 
addition of 3 #1 of the stop solution. 
The radioactivity  labeled samples were separated on a sequencing 
gel using the sequencing system  LKB 2010 Macrophor (Pharmacia 
LgS). 
For directly sequencing  of  the PCR fragments the T7-Sequenase- 
Kit from Pharmacia  LKB was used according to the following pro- 
cedure. The PCR products were first separated  on 3 to 4% NuSieve 
(Biozym)  agarose  gels and eluted using GENECLEAN II (Dianova, 
Hamburg, Germany). 4 #1 of isolated DNA at a concentration of 
10-20/~g/ml were added to 2 #1 annealing  buffer.  Then 2/zl primer 
solutions containing 300 ng of primer were added, followed by 
1.2/A of NP-40 (5%) and 2.8/A H20.  The complete annealing 
mixture (12/A) was briefly centrifuged using an Eppendorf cen- 
trifuge (Eppendorf, Hamburg, Germany)  and rapidly  heated  to 95~ 
for 3 min. Then the annealing  mixture was immediately  transferred 
to liquid nitrogen. For labeling 6 #1 of the labeling mixture (T7- 
Sequenase-Kit; Pharmacia, LKB), which consisted of 3/A Labeling- 
MIX, 0.5/zl ol-[3sS]-dATP (1,000 Ci/mmol), 2/zl T7-polymerase 
(2 U/#I), and 0.5/A NP-40 (5%), was added. 4 #1 aliquots were 
used for each dNTP. The labeling reaction was started by adding 
and briefly  centrifuging of the 4 #1 labeling mixtures to the respec- 
tive mixture consisting of 2 #1 of one of the four short mixes (A, 
C, G, T) and 0.5 #1 NP-40 (5%). Labeling was performed for 5 
min at 37~  Then 2 #1 of  a chase  mixture consisting  of  2 #ldNTPs 
(2.5 mM), 2 #1 NP-40 (5%),  2 #1 NaC1 (500 mM), and 14 #1 
H20 was added, briefly centrifuged and incubated for 5 min at 
37~  Finally, the reaction was stopped by adding 5 #1 stop solu- 
tion and briefly centrifuging. 
Y-RACE.  For an analysis of the 5'-ends of the La RNAs we 
chose the 5'-RACE system supplied  by GIBCO BILL  (Eggenstein, 
Germany). It includes a first strand cDNA synthesis and an PCR 
amplification step. During reverse transcription, 40 U of RNase 
inhibitor (Boehringer Mannheim) was added to each sample. The 
total KNA samples used were isolated from either (adult) liver of 
the tumor patient (We) with liver metastasis (1.4 #g), human em- 
bryonic (20 week) spleen (5 #g), PBL of the patient (Ma) with 
pSS (0.3 #g), PBL of a (adult) control person (0.6 #g). The reac- 
tions and the following 5'-RACE steps were performed according 
to the instructions of the supplier. For the first strand synthesis 
a primer locating within the exon 3 was used (TGTCCCGTG- 
GCAAATTGAAGTCGCC). Amplification was performed using 
the primers P20 and P12 in combination with the Anchor Primer 
of the 5'-RACE kit (GIBCO BRL, Eggenstein, Germany). 
Results 
Based on the suggestion that the development of autoan- 
tibodies to La protein in patients with SLE and pSS is at least 
partially driven by the autoantigen itself, one might expect 
an altered expression of the La gene in patients in dependence 
on disease conditions. Therefore, we looked for alternative 
forms of La mRNAs in tissue obtained from a La positive 
pSS patient (Ma)  (8). 
Isolation of Alternative  La cDNAs.  For that  purpose  a 
cDNA library was prepared from the patient's PBLs. This 
cDNA library was screened with the patient's own autoim- 
mune serum. Thereby five La cDNAs were isolated (Fig. 1). 
Three of them had derived from shortened La mRNAs starting 
within or downstream of the exon 2, as became already evi- 
dence from restriction enzyme fragment analysis (Fig. 1) and 
sequencing from the 5'- and 3'-end (data not shown). The 
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Figure  1.  Characterization  of the La cDNAs isolated from the cDNA 
library of the patient with pSS by immunoscreening  using restriction en- 
zyme fragment analysis.  The screening of the patient's cDNA library with 
her own autoimmune serum resulted in the isolation of five cDNAs (B; 
I-5)  that had been derived from La mRNAs. These La cDNAs showed 
a restriction enzyme  fragment pattern similar to the pattern of a La cDNA 
(A) described by Chan et al. (13). The clones with the two longest La 
inserts were termed as La23 (1) and La19 (2). The insert in the clone La19 
has the opposite orientation as in the other La clones. 
residual two La cDNAs (Fig.  1, clones 1 and 2, which were 
termed as La23 and LaD) were sequenced and their sequence 
was  given  to  the  EMBL  Data  Library  (EMBL  accession 
number X69804). Both La cDNAs were found to start up- 
stream of the exon 2, but displayed the following three un- 
usual properties:  (a)  they started  at  their 5' terminus  with 
an oligo(dT)-stretch;  (b) as already evident from the restric- 
tion enzyme fragment analysis (Fig.  1), the La cDNA insert 
was inverted in the clone La19, probably due to the presence 
of the oligo(dT)-stretch,  and;  (c) upstream ofexon 2, exactly 
at  the  splice  site,  the complete exon  1 was replaced by an 
unknown  5'-terminal  sequence,  termed  exon  1'  (Fig.  2). 
Downstream  of the exon 2,  the  sequence was identical  to 
the described La sequences (Fig.  2). 
Southern Blot Analysis.  To rule out a cloning artifact or 
the isolation of a splicing intermediate  the genomic origin 
of the  exon  1'  sequence  was  determined.  By  performing 
Southern blot experiments with genomic DNA of healthy 
individuals  and the patient  (Fig.  3) the exon 1' was located 
on a 4.8-kb EcoRI fragment (Fig. 3 A), which was described 
as containing  the exons  1 and  2,  as well as the  intron  be- 
tween them (17). In agreement,  the same fragment also hy- 
bridized  to  a probe being specific for the exon  1 sequence 
(Fig.  3 B) and was confirmed to be a part  of the La gene, 
as it also hybridized to a probe containing  the complete La 
cDNA sequence (Fig. 3 C). From this experiment it became 
also evident that the exon 1' sequence is not a patient specific 
sequence (Fig.  3, A-C, lane c) but exists in healthy donors 
as well (Fig.  3, A-C,  lanes a  and  b). 
The Genomic Origin of the Alternative  La cDNAs.  The next 
steps were to isolate the 4.8-kb fragment containing the exon 
1' sequence and to develop a sequencing scheme that allowed 
us to compare the  sequences from  healthy donors  and pa- 
tients. For that purpose the 4.8-kb fragment was subcloned 
from the genomic clone M.a2-1 (17) into pBluescript SK(-) 
and sequenced starting upstream of the proposed promoter 
of exon  1 going  downstream  through  the intron  into  the 
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Figure 2.  Characterization  of the alternative form of La mRNA. A 
comparison of the sequence derived from the La cDNAs La19 and La23 
(I; EMBL accession  number  X69804) with the human La cDNA described 
by Chanet al. (13) (II; EMBL accession number XD697) was performed. 
Upstream of the acceptor splice site at exon 2 (nt 216; [ ~ ]) the sequences 
differed, whereas the sequence downstream of the exon 1' is identical to 
the sequence described by Chanet al. (13). The La cDNAs La19 and La23 
started with an oligo(dT)-tail of different length (La19, 31 (dT)-residues; 
La23, 52 (dT)-residues). At the genomic level the length of the (dT)-tail 
was determined  with 23 (dT)-residues (see also Fig. 4 B). 
exon 2 using a series of primers as schematically summarized 
in Fig. 4 A.  The resulting complete genomic sequence was 
given to the EMBL Data Library (EMBL accession number 
Z35127)  and  is partially  shown in  Fig.  4 B. 
We identified the exon 1' sequence, including its oligo(dT)- 
tail, 325 nt downstream of the exon 1 donor splice site. From 
this result we concluded that  (a)  the exon  1'  sequence is a 
part of the intron between exon 1 and 2; (b) the alternative 
La  cDNAs  La19  and  La23  must  have  been  derived  from 
processed hnRNAs; and (c) the 5'-terminal oligo(dT)-tail of 
La19 and La23 was not  the result  of a cloning  artifact. 
Figure 3.  Southern blot experiment of the La gene. Genomic DNAs 
obtained from liver of a tumor patient (We, lane a), from PBL of either 
a healthy donor (lane b), or from the patient (Ma) with pSS (lane c) were 
analyzed. The same  blot was hybridized three times with probes specific 
for either exon 1' (A) or exon 1 (B) or the complete La gene (C). 
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P15"* 
~P16 
P17-=, 
EXON 2 
" P18 
,,- P19 
",- P20 
"  P21 
B 
i0  20  30  40  50 
5'  GGGCTGGGGT  ACAGACGCCG  TCCAGAAATA  CTTAAAAATA  AATGTTTATA 
60  70  80  90  100 
CTAACACAAA  CTAGCAGCCA  TTCCCCTACA  ACCTGGAGTA  CTTTTTAACC 
ii0  120  130  140  150 
CAATCTGTTT  GGGATTGAGGGCGGGACrCC  AGGGTCCCTG  GGAGGCCCCG 
(i)  ~ 
160  170  180  190  200 
GCAGCCGCGC  ATGCTCAGAG  CACAGGGACC  GCTCCACCTC  GTCCGTGGCC 
210  220  230  240  250 
CTGCCCACCC  AGGCCGCAAG  AGCTGCCGGG  ACGGTCCCCA  TCTTCTTGGA 
~> 
260  270  280  290  300 
GCGCTTTAGG  CTGGCCGGCG  GCGCTGGGAG  GTGGAGTCGT  TGCTGTTGCT 
310  320  330  340  ~  350 
GTTTGTGAGC  CTGTGGCGCG  GCTTCTGTGG  GCCGGAACCT  TAAAGGTGAG 
360  370  380  390  400 
TAACTCTCGG  TGGCTAATGA  GAAGCTACAAAAGGGTCCGC  TTTGCTGGTG 
(ii)  ~ 
410  420  430  440  450 
CGCGACTGCG  CGTTTCCGTT  CTTTACTGCT  TCTCGCGGCG  TCCGTCCGCC 
~> 
460  470  480  490  500 
CCTCGCCTTC  CTCACGTTCA  GGCCGAGCGC  CGCGTGGGCC  GCAGCCGGAG 
510  520  530  540  550 
GCGGCGGAGC  CGAGGGGGCG  CGGGCGGCGG  CGAGGCTGCC  CCCGCGAGGA 
560  570  580  590  600 
ATGCGGGATC  CTGGGGTTCC  CCGCACGTGG  CTGGTGCCCA  GGCAGTTCCG 
610  620  630  640  650 
CGGTTGCTTA  GAGACGGGAC  TGTGGCTGCC  CTCATCCCCA  TTGCGTCTTT 
660  670  680  690  700 
TTT~uu~TT  TTTTTTTTTTACCTCCAEUGCCTTCTAGTC  TCACCGAAGG 
710  720  730  740  750 
CTTGTGGCCA  TCTCTGTAAA  GTTTCTGGGGAGGTGGGCACGGGGTAAACG 
760  770  780  790  800 
C~TT  CTGTGGAGCC  TATGGGACTGACT~AAAGAACTTT 
810  820  830  840  850 
GGGCCGCAGA  TGTACACCAGCGTCACTCTT  TTGGTCTGTT~TCA 
860  870  880  ~  890  900 
TCGCTCACAT  CAGGTTTCAG  TGTGAAACGG  GAAAACGTGG  GTAATATTTC 
910  920  2250  2260 
ATTTACAGTC  GTACATTCTG  ....  //  ....  CGGGATATTA  ATACTTTGTA 
2270  2280  2290  2300  2310 
AACATTATCT  TTCTATTCTT  GAGTTTTATA  TAAAAAATAA  CTTTATGCTA 
2320  ~  2340  2350  2360 
ATTTGGGAAA  TTTTACAGAT  AGCCGCAATG  GCTGAAAATG  GTGATAATGA 
2370  2380  2390  2400 
AAAGATGGCT  GCCCTGGAGG  CCAAAATCTG  TCATCAAATT  GAG  3' 
Figure  4.  The promoter  regions,  the exon  1, 
the intron containing the exon  1', and exon 2  of 
the La/SS-B gene of DNA of the patient (Ma) and 
the genomic clone Ma2-1.  (A) The genomic re- 
gion starting  upstream of the promoter  of exon 
1 and ending downstream of the exon 2 was de- 
termined  using  the  21  primers  (Pl  to  P21  (see 
Materials and Methods)  as schematically shown. 
The complete sequence is available from the EMBL 
Data Library (EMBL accession number Z35127). 
(B) Sequencing started  118 nt upstream of the pro- 
moter region ((i) ....  ) described by Chambers 
et al.  (17);  nt 240  transcription  start  site (  |  ) 
of exon 1; nt 240-345  exon 1; nt 345 ( it ) donor 
splice site of exon  1; (it)  ....  putative alterna- 
tive TFIID binding site (TACAAA;  see also Fig. 
5); nt 413  transcription  start  site (|  of exon  1' 
as determined  with  5'-RACE;  nt 413-886  exon 
1'; nt 648-886  Y-end of the La cDNAs La19 and 
La23;  nt 886 ( ~ ) donor splice site of exon  1'; nt 
921-2240 of the intron containing at nt 1604-1904 
an Alu repeat  are not shown (...//...);  nt 2328 ac- 
ceptor splice site ( u ) ofexon 2; nt 2329-2403 exon 
2;  nt 2403  ( 1~ )  donor  splice site of exon  2. 
2063  Tr/Sster  et  al. The same sequencing scheme was then used to sequence 
the genomic DNA of the patient (Ma). The sequence of the 
genomic DNA of the patient (Ma) differed from M.a2-1 at 
nt  2003  with respect  to  a  conversion of the  nt T  to  C. 
Moreover, in one allele of the patients' DNA a deletion of 
the two nts (CA (1266/1267)  was found. However this dele- 
tion and the mutation is not common to other patients, as 
they were not found in the DNA of a female SLE patient 
or her baby born with AV block. A further point mutation 
(C to A) was found in the sequence  of the tumor patient 
(We)  with liver metastasis  at nt 495. 
GCN4-HIS3.4 
AP- I_CS4 
AP- I_C$3 
GTTTGTGAGCCTGTGGCGCGGCTTCTGTGGGCCGGAACCTTAAA6~TGAGTAACTCTCGG 
-113  .........  +  .........  + .........  +  .........  +  .........  +  .........  +  -54 
CAAACACTCGGACACCGCGCCGAAGACACCCGGCCT~AATTTCCACTCATTGAGAGCC 
TFIID-EIIa 
TGGCTAATGAGAAGCTACRARAGGGTCCGCTTTGCTGGTGCGCGACTGCGCGTTTCCGTT 
53  .........  +  .........  +  .........  +  .........  +  .........  +  .........  +  8 
ACCGATTACTCTTCGATGTTTTCCCAGGCGAAACGACCACGCGCTGACGCGCAAAGGCAA 
SPICS3 
(Spl)-U2snR. 
SpI-SV40.4 
SpI-IE-3.2 
Spl  CS2 
BGPI_RSI 
LSF-SV40 
Spl-IE-4/5.2 
SpI-IE-3.5 
Spl-IE-3.4  PEA3_CS 
TTRinverted  Pubox  TTRinverted 
UCE.I  SpI-IE~3.1  PKA3RS  zeste-Ubx 
CTTTACTGCTTCTCGCGGCGTCCGTCCGCCCCTCGCCTTCCTCACGTTCAGGCCGAC-CGC 
9  .........  +  .........  +  .........  +  .........  +  .........  +  .........  +  68 
GAAATGACGAAGAGCGCCGCAGGCAGGCGGGGAGCGGAAGGAGTC-CAAGTCCGGCTCGCG 
EGR-I_C5 
LSF-SV40 
Spl-IE-4/5.2 
Spl-IE-3.5 
Spl-IE-3.4 
Spl-IE-3.1 
SPI_C53 
(Spl)-U2snR. 
SpI-SV40.4 
Spl-IE-3.2 
SpI_CS2 
BGPI_RSI  AP-2CS5 
MRE-BPCS  N'ROX24_CS  AP-2CS4 
CGCGTGGGCCGCAGCCGGAGGCGGCGGAGCCGAGGGGGCGCGGGCGGCGGCGAGGCTGCC 
69  .........  +  .........  +  .........  +  .........  +  .........  §  .........  +  128 
GCGCACCCGGCGTCGGCCTCCGCCC,  CCTCGGCTCCCCCGCGCCCGCCC,  CCGCTCCGACGG 
MyoD-MCK-Ief  NFI_CS3 
NFkB  CS4  ABRE  USF-CVITII 
Pu  box  MCBF_RS  NFkB  CSI  NR(1)_CS  uteroglobin 
CCCGCGAGGAATGCGGGATCCTG~--@~CCCGCACGTGGCTGGTGCCCAGGCAGTTCCG 
129  .........  +  .........  +  .........  +  .........  +  .........  +  .........  +  188 
GGGCGCTCCTTACGCCCTAGGACCCCAAGGGGCGTGCACCGACCACGGGTCCGTCAAGGC 
AP-2_C55  MalT_C$ 
HSV.IE  repea  SIF_coreR5  malT  CS 
CGGTTGCTTAGAGACGGGACTGTGGCTGCCCTCATCCCCATTGCGTCTTTTTTTTTTTTT 
189  .........  +  .........  +  .......  +  ......  +  .........  +  .........  +  248 
GCCAACGAATCTCTGCCCTGACACCGACGGGAGTAGGGGTAACGCAGAAAAAAAAAAAAA 
Figure 5.  Consensus  sequences for transcription  factors.  The genomic 
sequence between  the Y-end  ofomn 1 (italics)  and the oligo(dT)-tail,  which 
is the start  of  the La  cDNAs  Lal9  and La23, was analyzed  for transcription 
factor consensus sequences using the program Husar (DKFZ). In agree- 
ment with the 5'-RACE result, a TFIID binding  site exists -37 nt up- 
stream of the transcription start site ( 4, nt 1). In addition, the sequence 
contains a series of further putative transcription  factor  binding sites, in- 
chding a NF-~B element. It should  be mentioned  that two heat shock 
protein (hsp) 70 transcription  factor  consensus  sequences are located  about 
270 nt upstream of the TACAAA  site,  which is already  upstream of the 
promotor  for the exon 1. Moreover, a true TATA  box locates  50 nt further 
upstream (not shown). 
Determination of the Alternative Transc@tion  Initiation Site  As 
the oligo(dT)-tail was found to be a true part of the alterna- 
tive La mRNA, it appeared  rather unlikely that it should 
be the transcription initiation site of the La mRNA. There- 
fore, in a further approach we looked for the transcription 
initiation site of the alternative La mRNA.  Using the 5'- 
RACE technique, the transcription start was determined to 
locate 235 nt upstream of the oligo(dT)-stretch, which is 68 
nt downstream of the exon 1 but still within the intron be- 
tween exon 1 and exon 2 (Fig.  4 B). By consequence,  the 
La gene might contain two promotor sites. One upstream 
of the exon I and an alternative promotor within the intron 
downstream of the exon 1'. Indeed searching for hypothet- 
ical transcription factor binding sites (Fig. 5) a hypothetical 
TFIID binding site was identified to locate  -37 nt upstream 
of the determined transcriptional start site (Figs. 4 and 5). 
A Mechanism Leading to the Alternative La mRNA Form.  In 
summary, we conclude that the alternative La mRNA is tran- 
scribed from an alternative promoter within the intron and 
represents the result of an alternative splicing event. The pro- 
posed mechanism leading to the two forms of La mRNAs 
is schematically summarized in Fig. 6 as follows: when the 
promotor upstream of exon 1 is used, the complete intron 
between exons 1 and 2 including the exon 1' sequence locating 
within the intron is removed during splicing. If the promotor 
upstream of exon 1' but downstream of the exon 1 is used, 
then (a) the exon 1 is not transcribed and (b) an alternative 
donor splice site within the intron is spliced to the same ac- 
ceptor splice site at the exon 2. At the mRNA level this results 
in a complete exchange of the exon 1 by the exon 1'. 
Properties of the Resulting Alternative La mRNA.  One major 
difference between the two types of La mRNAs is based on 
the existence of three ATGs in the exon 1'. As shown in Fig. 
7, there are two stop codons in the reading frame of the first 
ATG. The second ATG is in the  + 1 and the third ATG in 
the - 1 frame. Interestingly, upstream of the first ATG there 
are two GC-rich regions. 
Further Properties of the Analyzed Genomic Region of the La 
Gene.  Based on the presence  of the oligo(dT)-tail and of 
a further homopolymeric sequence,  an oligo(dA)-tail of 26 
(A)-residues (nt 1905-1930; EMBL accession number Z35127), 
which locates downstream of an Alu repeat (nt 1604--1904), 
we asked whether the alternative 5' terminus represents a part 
of a pseudogene. Comparison with the EMBL Data Library 
resuhed in the identification of a sequence element of 89 nt 
starting 153 nt upstream of the oligo(dT)-tail, which has ho- 
mologies in the range of 65%  to the reversed sequence  of 
the avian myelocytomatosis provirus and pseudorabies  virus 
(Fig. 8). The region of homology to the avian myelocytoma- 
tosis virus locates within the v-myc region of the gag-myc 
fusion protein. 
Discussion 
Frequently sera of patients with pSS and SLE contain au- 
toantibodies. One of the targets of the ANAs is the nuclear 
autoantigen La/SS-B (7). Different mechanisms had been dis- 
cussed for the development of the autoantibodies directed to 
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Figure 6.  Origin  of the  two different forms of La 
mRNAs. The La gene contains two alternative transcrip- 
tion start sites ( .t ). In the case of the exon 1 containing 
La mRNA the transcription start was originally deter- 
mined with primer extension (17). This site was confirmed 
by the use of  the 5'-RACE technique. The same technique 
was used to determine the initiation site of the exon 1' 
type La mRNA. It was found to locate  in the intron down- 
stream of the exon 1. By consequence, the two forms are 
expressed as follows:  when the promotor upstream of  exon 
1 is used, the complete intron between exon 1 and exon 
2, including the exon 1' sequence locating within the in- 
tron, is removed  during splicing. If  the promotor upstream 
of exon 1' but downstream of the exon 1 is used, (a) the 
exon 1 is not transcribed and (b) an alternative donor splice 
site within the intron is spliced to the same acceptor splice 
site at the exon 2. Thereby the exon 1 is replaced by the 
exon 1" One major difference between the two types of 
La mRNAs is based on the fact that the translation initia- 
tion site of the exon I type La mRNA locates in the exon 
2, since the exon 1 does not contain an ATG sequence. 
In contrast, the exon 1' contains three further ATGs. 
5' 
i0  20  30  40  50 
TTTCCGTTCT  TTACTGCTTC  TCGCGGCGTC CGTCCGCCCC  TCGCCTTCCT 
60  70  80  90  i00 
CACGTTCAGG  CCGAGCGCCG  CGTGGGCCGC AGCCGGAGGC  GGCGGAGCCG 
ii0  120  130  140  150 
AGGGGGCGCG  GGCGGCGGCG AGGCTGCCCC  CGCGAGGAAT  GCGGGATCCT 
M  R  D  P 
160  170  180  190  200 
GGGGTTCCCC  GCACGTGGCT  GGTGCCCAGG  CAGTTCCGCG  GTTGCTTAGA 
G  V  P  R  T  W  L  V  P  R  Q  F  R  G  A  L  E 
210  220  230  240  250 
GACGGGACTG  TGGCTGCCCT  CATCCCCATT GCGTCTTTTT  TTTTTTTTTT 
T  G  L  W  L  P  S  S  P  L  R  L  F  F  F  F  F 
260  270  280  290  300 
TTTTTTTTAC  CTCCACCGCC  TTCTAGTCTC ACCGAAGGCT  TGTGGCCATC 
F  F  T  S  T  A  F  *  S  H  R  R  L  V  A  I 
310  320  330  340  350 
TCTGTAAAGT  TTCTGGGGAG  GTGGGCACGG GGTAAACGCC  GGAGGGTTCT 
S  V  K  F  L  G  R  W  A  R  G  K  R  R  R  V  L 
360  370  380  390  400 
GTGGAGCCTA  TGGGACTGAC  TGGAGGCCAA AGAACTTTGG  GCCGCAGATG 
0  W  S  L  W  D  *  L  E  A  K  E  L  W  A  A  D  V 
-i  M 
+i  M  G  L  T  G  G  Q  R  T  L  G  R  R  C 
0 
-i 
+i 
410  420  430  440  450 
TACACCAGCG  TCACTCTTTT  GGTCTGTTAG GGCCTTCATC  GCTCACATCA 
H  Q  R  H  S  F  G  L  L  G  P  S  S  L  T  S 
Y  T  S  V  T  L  L  V  C  * 
TPASLFWSVRAFIAHIR 
460  470  ~  480  490  500 
GGTTTCAGTG  TGAAACGGGA AAACATAGCC  GCAATGGCTG AAAATGGTGA 
G  F  S  V  K  R  E  N  I  A  A  M  A  g  N  G  D 
+I  F  Q  C  E  T  G  K  H  S  R  N  G  *  *  * 
510  520  530  540  550 
TAATGAAAAG  ATGGCTGCCC  TGGAGGCCAA AATCTGTCAT  CAAATTGAGT 
0  N  E  K  M  A  A  L  g  A  K  I  C  H  Q  I  g  Y 
Figure 7.  The alternative 5' terminus contains three ATGs. All the 
hypothetical reading frames starting within the exon 1' are italics and un- 
derlined. Stop codons are indicated by (*).  Upstream of the first ATG 
the exon 1' sequence contains two GC-rich regions (underlined). The first 
reading frame contains two stop codons. The second ATG is in the  + 1 
frame, the third ATG in the -1 frame. The (  ) marks the splice  junction 
the nuclear antigen La/SS-B including either a molecular mim- 
icry with (retro)viral epitopes or an antigen driven mecha- 
nism  (5,  6). 
In case of an autoantigen driven mechanism alterations in 
patients  with  respect  to the expression of the autoantigen 
should occur. However, such pathophysiological alterations 
had not been described up to now. Therefore we started to 
analyze the expression of the La gene searching for alterna- 
tive transcripts  overexpressed in patients. 
For that purpose a cDNA library was made from PBL of 
the patient  (Ma;  8) with pSS and  the library was screened 
with her own autoimmune serum. Thereby a novel form of 
La mRNA  was identified.  The two isolated alternative  La 
cDNAs differed from the hitherto known La cDNA sequence 
at the 5' terminus. Both alternative La cDNAs started with 
an unusual 5'-oligo(dT)-tail and lacked the exon 1 sequence. 
Instead of the exon 1 an alternative 5'-terminal sequence which 
was termed as exon 1', was found.  Using the technique of 
Southern blotting, an EcoRI fragment was identified to con- 
tain the exon 1' in healthy donors as well as in patients. There- 
fore, we concluded that the exon 1' is not a patient-specific 
insert. The 4.8-kb fragment containing the exon 1' was sub- 
cloned from a genomic k done into pBhescript and sequenced. 
Thereby the exon 1' including its oligo(dT)-tail was found 
to be a part  of the intron between  exons  1 and 2. 
As the oligo(dT) was also found within the genomic se- 
quence, the presence of the oligo(dT)-tail at the 5' terminus 
of the cDNAs is not the result of a cloning artifact, although 
it must be mentioned that the length found for the genomic 
oligo(dT)-tail (23 [dT]-residues) was smaUer than the length 
of the oligo(dT)-tails of the cDNAs (31 [dT]-residues in the 
between exon 1' and exon 2. The proposed NH2-terminal aa sequence of 
the La protein (13), if translation starts at the first ATG in the exon 2 
(bold; nt 484). 
2065  Tr6ster  et al. (Z) 
70  80  90  100  110 
La  CCACCAGCCACGTGCGGGGAACCC~TCCCGCATTCCTC~-J~3GGGCAGA~CTC--GC 
IIIII  IIIII  II  It  IIIII  I 
rea,-,~h  ~CCC~C~CGCCTCCCGJI,  CCCGGCCCGCCGCCCTe,Q@GGC:CGICCGCCTCC~C 
2450  2460  2470  2480  2490  2500 
120  130  140  150  160  170 
La  CGCCGCCCGCGCCCCCTCGGCTCCGCCGCCTCCGGCTGCGGCCCACGCGGC6JCTCGGCCT 
IIIII  II  IIII  IIIIIII  I  III  I  II  II  II  II  I  I  III 
rea,,~h  CGCC~CCCG(:CGtCCTCGGC-CGGCC'~',CTACCTGC-ACC~ACCgL,  i~G(~gAJGCC'~<::~CC_,CC 
2510  2520  2530  2540  25~0  2560 
20  30  40  50  60  70 
La  GAT~.GCC~CCC.-iTC  TC  TJLI~GCGkGU&AC  TGCC  T~CJ~CCJ~CJ% 
Ill  i  II  il  J  Ill  lJ  lllJ 
r~29  CGCCGCCAAGCTGGAGAAGGTGGTGTO~C~C  TCGCCACCTAC~  CTCCC  GCCA 
2460  2470  2480  2490  2500  2510 
80  90  100  110  120 
La  CGTGCGGGG- -  -  AAC  CC~TCCCGCATTCCTCGCGGGGGCAGCC~CGCCGCCCG 
I  i  Jill  II  i  I  lJill  I  J  i  II  I  I  I  lJlJllJlJ 
ra~c29  ~  CCCGCC  GCCGC  C  TCCC  G-  AC  CCGGCCCGCCGCC  C  TCGGGGCCGCCGCC  TC 
2520  2530  2540  2550  2560  2570 
130  140  150  160  170  180 
La  CGCCCCCTCGGCTCCGCCGCCTCCGGC~CCACGCGGCGCTCGGCCTGAACGTGAG 
I  llJ  J  lJll  lJllllllJJ  I  I  lJ 
rt~c29  CTCCCGC-CGGCCCCGCCGCCTCGGCCGGCCTCTACCTGCACGACCTGGGAGCCGCGGCC 
2580  2590  2600  2610  2620  2630 
(III) 
30  40  50  60  70  80 
La  CAGTCCCGTCTCTAAGGAACCGCGGAAC  TGCC  TGGGCCACCAGCCACGTGC~CCC 
Ill  I  il  i  II  I  I  lJ  II  I 
hel~vie CC  TCCTCCTCGTCCTCGTCC TCCTCGTCCTCCTCGTCC -  TCGTCC  TCC  TCCGAGGGAGAA 
1430  1440  1450  1460  1470  1480 
90  i00  110  120  130  140 
La  CAGGATCCCGCATTCC-TCGCGGGGGCAGCCTCGCCGCCGCCCGCGCCCCCTCGGCTCCG 
l  II  I  I  III  I  III  I  I  lillil  IIII  I  I  II  II  IIIII 
he1~vie GAAGACGAAGGAGTCCGGCCCGGCGCCCCACTCGCCCGCGCCGGGCCC-CCACCGTCTCCG 
1490  1500  1510  1520  1530  1540 
150  160  170  180  190  200 
La  CCGCCTCCGGCTGCGGCCCACGCGGCGCTCGGCCTGAACGTGAGGAAGGC~GGA 
III  I  II  II  llllill  llllll  illlllll 
hepvie  CC~CGCCCGCCGCGGCCC-CGCGGCCCTCGGCCTCCTCCGCCTCCGCCACCTCCTCCTC 
1550  1560  1570  1580  1590  1600 
Figure 8.  Sequence  homologies  of the 5'-end  upstream  of the oligo(dT)- 
tail. Comparisons  of the reversed sequence upstream of the oligo(dT)-tail 
with the EMBL DNA Data Library  revealed homologies of (a) 67.5% 
to a 83 bp overlap within the v-myc region of the avian  myelocytomatosis 
HBI provirus (reacmh; EMBL  accession  number Ml1784); (b) 60.8% ho- 
mology to a 120 bp overlap encoding  for the gag-myc  fusion  protein of 
the avian myelocytomatosis  virus of the same region (remc; EMBL  acces- 
sion numbers  V01174 and  J02247); or (c) 64% homology  to a 125-bp overlap 
ofan immediate-early  gene  of pseudorabies  virus (helwie; EMBL  accession 
number X15120). 
case of La19 and 52 in the case of La23). In fact these differ- 
ences may have resulted during the cloning procedure. 
By comparing the La cDNA sequences with the genomic 
sequence all the used splice sites became evident, including 
the exon 1 intron donor splice site, the alternative exon 1' 
intron donor splice site and the common intron exon 2 ac- 
ceptor splice site. As the genomic sequence contains a 1443- 
nt-long intron between the 3'-end of the exon 1' and the 5'- 
start of the exon 2, which is absent in the sequence of the 
La cDNAs La19 and La23, it is clear that these La cDNAs 
must have been derived from alternatively spliced La mRNAs. 
Using the 5'-RACE technique the transcription initiation 
site of the alternative La mRNA was determined to locate 
68 nt downstream of the exon 1 donor splice site. According 
to this result, the transcription of the alternative La mRNA 
starts within the intron between exon 1 and exon 1'. There- 
fore, an alternative promotor might locate upstream of this 
alternative transcription initiation site. Indeed, searching for 
putative transcription factor binding sites  resulted in  the 
identification of a putative TFIID binding site at the expected 
position (Fig.  5).  It is interesting to note that in addition 
to the TFIID binding site a series of further consensus se- 
quences for other transcription factors,  which could be in- 
volved in regulation of a differential expression  of the two 
types of La mRNAs, exists in the intron downstream of the 
exon 1 as summarized in Fig.  5. These transcription factor 
binding sites include common transcription factors such as 
SP1 but also of the AP1 and AP2 family. Of most interest 
is the presence  of a NF-KB element 218 nt downstream of 
the exon 1, as NF-KB is known to be activated by UV irradi- 
ation, dsRNA, acute phase proteins, including some inter- 
leukins, interferons, tumor necrosis factor, and retroviruses 
(26). Moreover, NF-KB elements also exist in retroviruses and 
are assumed to be involved in activation of retroviruses,  viral 
latency, and development of autoimmunity. The NF-KB ele- 
ment in the La gene (5'-GGGGTTCCCC) is very similar 
to the NF-KB binding site in the HIV virus (5'-GGGGAT- 
TCCCC), which has been described to cause symptoms similar 
to pSS (4). 
Taken together, the conditions known to activate NF-KB 
are the conditions known to cause and induce acute disease 
in SLE patients. Therefore, it is tempting to speculate  that 
here could be a first hint for a link between the development 
of disease as well as inducers of acute disease and an alterna- 
tive expression  of the gene encoding for the  autoantigen 
La/SS-B. 
In summary our genomic data show that the mechanism 
leading to the alternative form of La mRNA includes a pro- 
motor switching and an alternative splicing event. 
At present the function of the alternative La mRNA re- 
mains obscure,  as the complete exon 1' as determined with 
the 5'-RACE experiment does not only contain the unusual 
oligo(dT)-tail, but also two GC-rich regions and three ATGs. 
However,  there are two stop codons in the reading frame of 
the first ATG. Moreover,  the second and the third ATG are 
not in the correct reading frame (Fig.  7).  Similar looking 
alternative transcripts had been described for other house- 
keeping proteins. In these cases it had been suggested that 
the alternative transcripts either are not translated into pro- 
tein but should throttle the translation or represent stored 
intermediates for a further tissue-dependent 5'-terminal pro- 
cessing  (18). 
By consequence,  future studies are required to clarify the 
physiological function of the alternative La mRNA. Moreover, 
the behavior under pathophysiological conditions must be 
elucidated.  For  example it  is  well  established  that  active 
retroviruses  take use of read through of stop codons and 
ribosomal frame shifrings during translation of their proteins. 
2066  Alternative  Transcript Encoding for the Autoantigen  La/SS-B So it is tempting to speculate that similar events could occur 
during translation of the alternative LamP,  NA in retroviral 
infected cells leading to NH2 terminally altered La proteins, 
which could finally induce the autoimmune reactions against 
the La protein. 
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